Of recent interest are new targeted therapies such as Tarceva<sup>®</sup> (erlotinib), an epidermal growth factor receptor (EGFR) inhibitor, for treatment of recurrent thymic carcinoma. Here, EGFR is linked to thymic carcinoma.